IPO: Absci Corporation Aims For Proteins As Next-Generation Therapeutics

IPO: Absci Corporation Aims For Proteins As Next-Generation Therapeutics

Absci Corp describes itself as an AI-powered integrated drug creation platform. The company creates protein-based drugs (biologics) by unifying biologic drug discovery and cell line development into one process. This places Absci squarely under the umbrella of synthetic biology. The challenge in next-generation biologics is the linear steps needed to screen and select desired molecular … Read more

Categories IPO

IPO: Caribou Biosciences Advances Cell Therapy With CRISPR

IPO: Caribou Biosciences Advances Cell Therapy With CRISPR

Caribou Biosciences is a clinical-stage biopharmaceutical company innovating in next-generation, genome-edited cell therapies. Its CRISPR hybrid RNA-DNA (chRDNA) guide technology has demonstrated superior specificity and high efficiency in preclinical studies, and, according to the company, has the potential to generate gene and cell therapies in oncology and in therapeutic areas beyond oncology, including immune cell … Read more

Categories IPO

IPO: Verve Therapeutics Takes On Cardiovascular Disease Using Gene Editing

IPO: Verve Therapeutics Takes On Cardiovascular Disease Using Gene Editing

Verve Therapeutics, a biotech company innovating new approaches to the care of cardiovascular disease with single-course gene editing medicines, announced terms for its $201 million IPO on today. Insiders Wellington Management and Casdin Capital and new investor Fidelity have indicated an interest in purchasing up to an aggregate $75 million worth of shares in the … Read more

IPO: Zymergen’s Valuation Soars to $8 Billion On Market Debut

IPO: Zymergen’s Valuation Soars to $8 Billion On Market Debut

Zymergen, an Emeryville, California–based synthetic biotechnology firm, recently raised $500 million in an initial public offering (IPO) of stock on the NASDAQ exchange that values the 8-year-old company at over $3 billion. Four months ago, Zymergen launched its first product, Hyaline, a polymer film for electronic displays that it developed with Sumitomo Chemical. Zymergen makes … Read more

Categories IPO

World’s Biggest Growth Investors Pool Assets To SPAC & PIPE Ginko Bioworks

World’s Biggest Growth Investors Pool Assets To SPAC & PIPE Ginko Bioworks

Ginkgo Bioworks, Inc.’s (“Ginkgo”) founders have been working together for nearly twenty years since they first met at MIT. They launched Ginkgo in 2008 with the consistent goal of developing a platform that makes cell programming easier for their customers and partners. Ginkgo’s platform leverages advanced robotic automation, proprietary software, and data analytics to continuously … Read more

Categories IPO

Here Is Another PIPE & SPAC Combo In The Proteomics Space

Here Is Another PIPE & SPAC Combo In The Proteomics Space

Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform for quantifying the human proteome, and Arya Sciences Acquisition Corp III, a special purpose acquisition company or SPAC, sponsored by Perceptive Advisors, announced in February a definitive business combination agreement. The combined company is expected to receive proceeds of approximately $350 million at the closing … Read more

Categories IPO

IPO: NexImmune Deploys Synthetic Dendritic Cells To Fight Cancer

IPO: NexImmune Deploys Synthetic Dendritic Cells To Fight Cancer

NexImmune, Inc, based in Gaithersburg, MD, is a clinical-stage biotechnology company developing immunotherapies that employ the body’s own T cells to generate a specific, potent and durable immune response that mimics natural biology. The company’s nanotechnology platform was originally developed at Johns Hopkins University. The backbone of the company’s approach is its Artificial Immune Modulation, … Read more

Categories IPO